ISRCTN83863387已完成2 期
Clinical trial to explore treatment effects of Ginkgo biloba extract EGb 761® in patients with chronic tinnitus and effect modification by etiology, biological factors and concomitant pathologies
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 187
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Outpatient male or female patient at least 18 years old
- •2. Chronic tinnitus
- •2.1. May be unilateral or bilateral, with or without concomitant hearing loss
- •2.2. Grade according to Biesinger is 2 or 3*
- •2.3. Duration of at least 3 months
- •3. Written informed consent to participate in the clinical trial, to trial-related treatment and to data recording in accordance with applicable laws
- •*Grade 2: The tinnitus is mainly perceived in silence and is disturbing under stress and strain.
- •Grade 3: The tinnitus causes permanent impairment in personal and occupational spheres. Emotional, cognitive and somatic disorders are present.
排除标准
- •1. Participation in another experimental drug trial at the same time or within the past 4 weeks before the baseline visit
- •2. Tinnitus due to Ménière's disease, vestibular schwannoma or otosclerosis
- •3. Any other drug treatments for tinnitus taken currently or within 2 weeks before the baseline visit
- •4. Gingko biloba preparation for any reason taken currently or within 4 weeks before the baseline visit
- •5. Cognitive behavioral therapy or tinnitus retraining therapy started within 6 months prior to the baseline visit or planned to be started during the course of the trial
- •6. Acute or chronic otitis media or acute vestibular neuritis
- •7. Ongoing psychiatric disorder, such as major depression, generalized anxiety disorder, schizophrenia, etc.
- •Of note: Symptoms of depression or anxiety or other behavioral or psychological symptoms at sub-syndromal level and not requiring treatment with psychotropic drugs are permitted.
- •8. Ongoing severe cardiac or circulatory disorder:
- •8.1. Severe (Canadian Cardiovascular Society stage IV) or unstable angina pectoris
- •8.2. Decompensated congestive heart failure (NYHA stage IV)
- •8.3. Uncontrolled hypertension with systolic blood pressure above 180 mmHg and / or diastolic blood pressure above 115 mmHg
- •8.4. Clinically significant cardiac arrhythmias (Lown classes IVb and V, bifascicular bundle branch block)
- •9. Severe renal or hepatic dysfunction (defined by serum creatinine or serum ASAT, ALAT or gamma-GT above 3 times the upper limit of the reference range in the anamnesis)
- •10. Ongoing uncontrolled endocrine or hematological disorder
- •11. Intake of drugs not permitted during participation in the trial, in particular, psychoactive drugs, systemic acting perfusion-enhancing drugs, cognition enhancing drugs, systemic acting anti-cholinergic drugs, regular use of anticoagulants (platelet aggregation inhibitors permitted) during the 2 weeks prior to the baseline visit
- •12. Ongoing hemorrhagic diathesis or coagulation disorder
- •13. Seizure within 2 years prior to Baseline Visit or regular use of anticonvulsive drugs
- •14. Active malignant disease (exception: prostate cancer which does not require other than hormone treatment within the next 6 months).
- •15. Known hypersensitivity to Ginkgo biloba extract or to excipients contained in the tablets
- •16. Active peptic ulcer disease or any gastrointestinal disease with potential impairment of the absorption of orally applied drugs (e.g. Billroth I/II, Crohn's disease, ulcerative colitis, any kind of enterectomy)
- •17. Female patients of childbearing potential without safe contraception (any form of hormonal contraception, intrauterine devices, sexual abstinence and partner sterilization are considered sufficiently safe when used consistently and correctly; child-bearing potential can be denied in case of postmenopausal state for at least 2 years, hysterectomy, bilateral tubal ligation or bilateral oophorectomy)
- •18. Planned surgical intervention requiring hospitalization during the clinical trial
- •19. Previous inclusion in the present clinical trial
- •20. Incapability of understanding nature, mea
研究者
相似试验
已完成
2 期
Clinical trial to explore treatment effects of Ginkgo biloba Extract EGb 761® in patients with different types of vertigo and effect modification by type of vertigo, chronicity and concomitant pathologiesISRCTN83227991Dr Willmar Schwabe GmbH & Co. KG206
已完成
1 期
Effects of Ginkgo biloba extract on blood levels of the drug rivaroxaban and on blood clottingPharmacokinetics and pharmacodynamics of rivaroxabanISRCTN41838730Dr. W. Schwabe GmbH & Co. KG42
进行中（未招募）
1 期
Clinical Trial to Explore Treatment Effects of Ginkgo biloba Extract EGb 761® in Patients with Different Types of Vertigo and Effect Modification by Type of Vertigo, Chronicity and Concomitant PathologiesDifferent types of vertigoMedDRA version: 20.0Level: PTClassification code 10047340Term: VertigoSystem Organ Class: 10013993 - Ear and labyrinth disordersEUCTR2016-000316-15-PLDr. Willmar Schwabe GmbH & Co. KG175
进行中（未招募）
1 期
Clinical Trial to Explore Treatment Effects of Ginkgo biloba Extract EGb 761® in Patients with Chronic Tinnitus and Effect Modification by Etiology, Biological Factors and Concomitant Pathologies.Chronic TinnitusMedDRA version: 20.0Level: PTClassification code 10043882Term: TinnitusSystem Organ Class: 10013993 - Ear and labyrinth disordersEUCTR2016-000315-32-PLDr. Willmar Schwabe GmbH & Co. KG175
已完成
1 期
Effects of growth hormone on status of children with cystic fibrosisCystic fibrosis with pulmonary manifestations.Cystic fibrosis with pulmonary manifestationsIRCT201112275330N3Vice chancellor for research, Tabriz University of Medical Sciences20